Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
220
-
Total 13F shares, excl. options
-
92.9M
-
Shares change
-
-640K
-
Total reported value, excl. options
-
$1.45B
-
Value change
-
-$11.4M
-
Put/Call ratio
-
0.27
-
Number of buys
-
83
-
Number of sells
-
-110
-
Price
-
$15.63
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q3 2024
271 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q3 2024.
NovoCure Ltd - Common Stock (NVCR) has 220 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 92.9M shares
of 112M outstanding shares and own 82.94% of the company stock.
Largest 10 shareholders include FMR LLC (16.2M shares), BlackRock, Inc. (12.8M shares), VANGUARD GROUP INC (11.8M shares), Capital International Investors (7.92M shares), Capital World Investors (4.31M shares), Nordwand Advisors, LLC (3.03M shares), T. Rowe Price Investment Management, Inc. (2.81M shares), STATE STREET CORP (2.73M shares), GEODE CAPITAL MANAGEMENT, LLC (2.41M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (2.32M shares).
This table shows the top 220 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.